Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 17Terminated 11Recruiting 9Active not recruiting 7Withdrawn 4Unknown 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 36Thoracic 30Genitourinary 23CNS 18Breast 11Tumor-Agnostic 3Head & Neck 3Sarcoma 1Other solid neoplasm 1Gynecologic 1Endocrine 1Dermatologic 1

Conditions

Uveal Melanoma 1Neoplasm Metastasis 1

Interventions

Nivolumab 27pembrolizumab 22Ipilimumab 17Temozolomide 13toripalimab 12Biopsy 10Cyclophosphamide 9Imiquimod 8Dacarbazine 7Blood Specimen Collection 7camrelizumab 6Chemotherapy, Adjuvant 6trametinib 5fludarabine 5dabrafenib 5atezolizumab 5aldesleukin 5Gene Expression Profiling 5Cisplatin 5Aminolevulinic Acid 5fludarabine phosphate 4durvalumab 4binimetinib 4apatinib 4Tomography, Optical Coherence 4Sorafenib 4Photochemotherapy 4Interleukin-2 4Injections 4Carboplatin 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Unknown × Radiosurgery × Dermatologic × Clear all
NCT05077280 2022-12-06

A Study of Concurrent Stereotactic Body Radiotherapy With Opdualag in Metastatic Uveal Melanoma

California Pacific Medical Center Research Institute

Phase 2 Unknown
40 enrolled
Dermatologic

Uveal Melanoma, Neoplasm Metastasis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡